Equities

Mach7 Technologies Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mach7 Technologies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.355
  • Today's Change0.00 / 0.00%
  • Shares traded15.17k
  • 1 Year change-13.41%
  • Beta1.4270
Data delayed at least 20 minutes, as of Feb 16 2026 04:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mach7 Technologies Limited is an Australia-based global healthcare software company. The principal activity is the development and commercialization of medical imaging and data management software solutions for global healthcare organizations. The Mach7 eUnity Enterprise Diagnostic Viewer is a zero-footprint viewer that allows medical professionals to remotely access patients' medical images at any location, from any device, without loss of speed or image quality. The Mach7 Vendor Neutral Archive (VNA) is a vendor agnostic data management solution that includes administration tools that allow for the fast storage, access, retrieval and viewing of images across a healthcare network. Mach7's Workflow Applications is designed to promote better clinical decision-making by giving users tools and worklists that provide access to contextual patient data and images.

  • Revenue in AUD (TTM)34.64m
  • Net income in AUD-6.20m
  • Incorporated1977
  • Employees90.00
  • Location
    Mach7 Technologies LtdLevel 4, 100 Albert RoadMELBOURNE 3205AustraliaAUS
  • Phone+61 39692-7222
  • Fax+61 39645-4707
  • Websitehttps://mach7t.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BCAL Diagnostics Ltd2.65m-7.24m44.17m----7.06--16.67-0.0201-0.02010.00740.0170.239--0.9573---65.31-57.98-87.92-72.00-----273.21-249.54----0.2766---13.0143.11-13.14--190.46--
HeraMED Ltd322.93k-4.53m44.55m----60.80--137.94-0.0059-0.00590.00040.00070.13810.37941.57---193.87-129.03-316.53-221.1458.7058.67-1,404.05-2,178.902.33--0.468---39.9011.7418.96------
Nova Eye Medical Ltd29.27m-9.06m47.00m130.00--2.47--1.61-0.0373-0.03730.11830.06681.042.927.08---32.13-21.38-39.78-24.9764.5478.66-30.95-46.441.85-121.420.1372--24.8117.95-3.06---14.69--
Cleanspace Holdings Ltd19.76m-478.27k50.16m----2.61113.572.54-0.0062-0.00620.25380.24480.73721.954.94---1.78-6.87-2.07-8.2974.7674.57-2.42-10.494.46--0.1914--25.72-6.9984.71---23.72--
Vitasora Health Ltd3.71m-10.11m50.17m2.00--2.90--13.54-0.0071-0.00710.00270.00930.30130.01064.17---82.17-118.94-115.44-176.5499.1978.72-272.73-533.630.6694--0.0039--256.7710.92-41.74------
Micro-X Ltd13.05m-13.90m58.81m----7.16--4.51-0.023-0.0230.02140.01130.53280.56653.51---56.71-41.13-95.63-53.7279.0568.51-106.45-104.841.13-30.400.464---14.2511.56-42.29---46.10--
Singular Health Group Ltd702.02k-6.26m67.50m----4.95--96.15-0.0258-0.02660.0030.04340.0848--7.39---75.64-120.64-86.15-162.51-----892.01-824.18---599.390.00---25.7740.56-117.55---1.59--
Compumedics Ltd50.83m-1.27m70.92m175.00--3.1475.931.40-0.0068-0.00680.2700.11291.071.643.91290,451.40-2.68-2.60-6.10-4.9254.9352.69-2.49-2.480.64560.68550.39--2.237.71-275.15--11.67--
Mach7 Technologies Ltd34.64m-6.20m83.43m90.00--1.8380.092.41-0.0259-0.02590.14430.1940.5048--6.07---9.04-7.68-11.51-9.1094.2495.77-17.90-20.36---26.290.024--15.4212.9322.19--84.49--
Vitrafy Life Sciences Ltd66.28k-14.15m85.41m----5.04--1,288.58-0.1807-0.18070.00080.33910.0022--0.2465---47.44---49.60-------21,351.00------0.0158--75.17---213.76------
Optiscan Imaging Ltd951.95k-6.31m88.76m8.00--9.27--93.23-0.0075-0.00750.00110.00920.07270.2570.5149---48.21-49.13-55.07-57.0650.4111.82-663.05-405.674.76--0.1611---17.62-4.38-4.15--35.75--
Cyclopharm Limited29.68m-13.38m100.11m95.00--2.56--3.37-0.1214-0.12140.26940.32480.49460.93066.28312,380.80-22.29-15.69-27.32-18.7361.4867.79-45.07-31.551.94--0.181---0.69414.35-180.75--15.28--
SDI Ltd110.38m12.16m106.38m300.008.751.046.250.96380.10230.10230.92870.86380.78331.455.43--8.637.8110.319.2962.8559.8611.029.061.6228.730.144842.64-0.739210.3816.6923.4713.5312.94
Austco Healthcare Ltd81.41m5.93m118.05m174.0019.682.2213.421.450.0160.0160.21970.14211.023.914.67--7.439.3510.8313.3352.0553.077.298.391.28--0.1233--39.9819.76-16.1518.8325.65--
Data as of Feb 16 2026. Currency figures normalised to Mach7 Technologies Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

52.83%Per cent of shares held by top holders
HolderShares% Held
Australian Ethical Investments Ltd. (Investment Management)as of 10 Oct 202537.46m15.94%
Sandhurst Trustees Ltd.as of 01 Oct 202531.84m13.55%
JM Financial Group Ltd.as of 01 Oct 202528.37m12.08%
Microequities Asset Management Pty Ltd. (Invt Mgmt)as of 24 Nov 202525.55m10.88%
Netwealth Investments Ltd.as of 01 Oct 2025891.57k0.38%
Dimensional Fund Advisors Ltd.as of 30 Nov 202513.05k0.01%
Dimensional Fund Advisors LPas of 05 Feb 20261.18k0.00%
Norges Bank Investment Managementas of 30 Jun 20250.000.00%
More ▼
Data from 01 Oct 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.